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Abstract
Genetics has an important role in the risk stratification and management of the patients
with acute myeloid leukemia (AML). Molecular testing can’t take the place of cytogenetic
testing results, but has complementary role to help refine prognosis of the disease, espe-
cially within specific AML subgroups. Molecular genetic analysis of CEBPA, NPM1, and
FLT3 is already the standard of care in AML patients, and mutations in several additional
genes are assuming increasing importance. The French-American-British (FAB) classifica-
tion and the World Health Organization (WHO) classification are the most classifications
for AML. The aim of this chapter is a review on the role of genetic analysis in new
treatments of AML.
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1. Introduction
Acute myeloid leukemia is the most common acute leukemia in adults and highly heteroge-
neous disease, characterized by gene mutations, chromosome abnormalities, changes in
expression of multiple genes, and microRNAs [1]. In 2008, World Health Organization
(WHO) categorized acute myeloid leukemia into four groups; AML with genetic abnormali-
ties, AML with myelodysplasia, treatment-dependent AML, and AML not categorized. In the
first group, prognosis depends on cytogenetic findings, so patients with acute myeloid leuke-
mia were divided into different prognostic groups. For example, the translocations t(8;21), t
(15;17), and inv(16) indicate a favorable prognosis, whereas 11q23 abnormalities indicate
intermediate or worse prognosis. In the last group, 40–50% of AML cases were included, and
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no chromosomal abnormalities were detected by conventional karyotyping. Almost these
patients located into the intermediate prognostic group [2]. The French-American-British
(FAB) classification system divides AML into eight subtypes, M0 through to M7, based on the
morphological and cysto-chemical characteristics of the leukemic cells as shown in Table 1.
This is done by examining the appearance of the malignant cells with light microscopy and/or
by using cytogenetics to characterize any underlying chromosomal abnormalities [4]. In AML,
somatic genetic changes are often thought to contribute to leukemogenesis through a “two-hit”
process: (1) mutations that activate signal transduction pathways and thereby increase the
proliferation or survival, or both, of hematopoietic progenitor cells (class I; Mutations in KIT,
FLT3, and N-RAS) and (2) mutations that affect transcription factors or components of the cell-
cycle machinery and cause impaired differentiation (class II; RUNX1, CBFβ, CEBPA, NPM1,
PU1, MLL, and RARA) [5]. Genes that were significantly mutated in AML were organized into
several functional categories (Figure 1) [6]. The purpose of AML genetic testing and classifica-
tion at diagnosis is mainly to risk-stratify patients with AML, and thus determine proper
treatment modalities.
2. Class I mutations
2.1. KIT mutations
KIT is a member of the type III RTK family, encodes a receptor tyrosine kinase and ligand-
independent activation of KIT. KIT mutations are detected mostly in association with core
binding factor (CBF) AML, and correlated with t(8;21), inv (16), and t(16;16) [7, 8].
Type Name Cytogenetics Percentage of adults
with AML (%)
M0 Acute myeloblastic leukemia, minimally differentiated 5 [3]
M1 Acute myeloblastic leukemia, without maturation 15 [3]
M2 Acute myeloblastic leukemia, with granulocytic maturation t(8;21)(q22;q22), t(6;9) 25 [3]
M3 Promyelocytic, or acute promyelocytic leukemia (APL) t(15;17) 10 [3]
M4 Acute myelomonocytic leukemia inv (16)(p13q22), del(16q) 20 [3]
M4eo Myelomonocytic together with bone marrow eosinophilia inv (16), t(16;16) 5 [3]
M5 Acute monoblastic leukemia (M5a) or acute monocytic
leukemia (M5b)
del (11q), t(9;11), t(11;19) 10 [3]
M6 Acute erythroid leukemia, including erythroleukemia (M6a)
and very rare pure erythroid leukemia (M6b)
5 [3]
M7 Acute megakaryoblastic leukemia t(1;22) 5 [3]
Table 1. French-American-British (FAB) classification of acute myeloid leukemia (AML).
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2.2. FLT3 mutations
Fms-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase involved in proliferation, cell
survival, and differentiation of hematopoietic progenitor stem cells. FLT3 mutations are one of
the most common genetic changes in AML that occur in about 30% of these cases and confer a
poor prognosis [9, 10]. Internal tandem duplications (ITD) mutations in the juxtamembrane (JM)
domain and missense point mutations in the second tyrosine kinase domain (TKD) of the FLT3
gene are the molecular abnormalities that have been found in 20% of all AML patients [11].
Figure 1. Acute myeloid leukemia and commonly mutated genes. Upper-left box shows mutations in FLT3 signaling that
confer a proliferative through the RAS–RAF, PI3K–AKT, and JAK–STAT signaling pathways. Upper-middle box shows
TP53 mutations, can lead to deregulation of transcription and impaired degradation through the phosphatase and tensin
homolog (PTEN) and the mouse double minute 2 (MDM2) homolog. Upper-right box shows DNMT3A and TET2
mutations, also IDH1 and IDH2 mutations, can lead to the deregulation of DNA methylation. Center-right box shows
mutations of ASXL1 and EZH2 genes, cause deregulation of chromatin modification, also KMT2A-MLLT3 gene fusion,
can impair other methyltransferases such as DOT1L. In center-right box shows RUNX1 and RUNX1-RUNX1T1 muta-
tions, result in reduced hematopoietic differentiation and transcriptional deregulation. Center-middle box shows muta-
tions in the RAD21 and STAG2, might impair accurate chromosome segregation and transcriptional regulation. Lower-
right box shows mutations of U2AF1, ZRSR2, SF3B1, SRSF2 are involved in deregulated RNA processing. Lower-left box
shows NPM1 gene mutations, resulting in the aberrant cytoplasmic localization of NPM1 and NPM1-interacting proteins.
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2.3. RAS mutations
Mutations in N-RAS and K-RAS occur in AML as well as solid Tumors in about 10 and 5% of
AML patients, respectively [12].
3. Class II mutations
In addition to class I mutations, in AML patients, mutations in brain and acute leukemia gene
(BAAL), MLL-MLLT3 gene fusion created by the t(9;11)(p22;q23) translocation is associated
with intermediate prognosis in AML, nucleoplasmin 1(NPM1), CCAAT/enhancer-binding
protein α (CEBPα), and Wilms tumor gene (WT-1) have also been detected. Lately, mutations
in DNMT3A, encode DNA methyltransferases that catalyze the addition of a methyl group to
the cytosine residue of CpG dinucleotides, have been recognized in one-third of de novo AML
patients with intermediate-risk cytogenetics. Genomes with DNMT3A mutations commonly
harbored extra mutations in NPM1, IDH1, and FLT3. The incidence of any DNMT3A muta-
tion, alone or in combination with FLT3 ITD mutation, is related with lower overall survival
(OS) [12, 13].
4. Molecule analysis of mutations in AML
The single most important prognostic factor in AML is cytogenetic testing of bone marrow
samples. Results are highly predictive of response to induction chemotherapy, relapse risk, and
overall survival (OS). Approximately 50–60% of newly diagnosed AML patients can be
detected by cytogenetic abnormalities [14]. To recognize cytogenetic abnormalities,
Risk Cytogenetics Molecular
Favorable inv (16) or t(16;16)
t(8;21)
t(15;17)
Normal cytogenetics with:
Isolated biallelic CEBPAmutation
NPM1mutation without FLT3 ITD
Intermediate Normal cytogenetics
Isolated +8
t(9;11)
Other non-good and non-poor changes
KITmutation in core binding factor leukemia:
inv (16) or t(16;16)
t(8;21)
Poor Complex (≥3 clonal abnormalities)
Monosomal karyotype
5/5q or  7/7q
11q23 rearrangements other than t(9;11)
inv (3) or t(3;3)
t(6;9)
t(9;22)
Normal cytogenetics with: FLT3 ITD
Table 2. Genetic risk classification of acute myeloid leukemia.
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fluorescence in-situ hybridization technique (FISH) and DNA analysis should be done as well
routine cytogenetics. Results of these tests are used for patient-risk stratification and to guide
patient management. In Table 2, most of the prognostic cytogenetic abnormalities are listed,
grouped by risk category [15]. AML Patients with the t(8;21)(q22;q22), t(15;17)(q22;q12), and
inv (16)(p13.1;q22) are associated with longer survival and remission, whereas alterations of
chromosomes 7, 5, complex karyotype, and 11q23 are associated with poor response to ther-
apy and shorter overall survival [16]. The vital chromosomal abnormalities in AML include
deletions in chromosomes 5 or 7 or monosomies and trisomy 8 [17]. Furthermore, other
abnormalities consist of the balanced translocations between chromosomes 15 and 17 (t
(15;17)); long arm of chromosome 11 (11q); chromosomes 8 and 21 (t(8;21)); (q22;q22), (q31;
q22), and t(9;11); and inversion for instance inv (16) [18].
5. Oncofusion proteins related with AML
In total, 749 chromosomal aberrations have been recorded in AML [19]. Table 3 shows the
common chromosomal aberrations and their corresponding Oncofusion Proteins in AML [12].
In conclusion, AML is a highly aggressive heterogeneous malignant disease, classified by
genetic abnormalities that define subgroups of distinct biological and clinical features. Despite
best efforts at targeted therapy, therapeutic approaches have stuck to “one-size fits all” con-
ventional chemotherapy because of lack of targeted therapeutic options.
Translocations Oncofusion protein Frequency of occurrence (% of AML)
t(8;21) AML1-ETO 10
t(15;17) PML-RARα 10
inv(16) CBFβ-MYH11 5
der(11q23) MLL-fusions 4
t(9;22) BCR-ABL1 2
t(6;9) DEK-CAN 1
t(1;22) OTT-MAL <1
t(8;16) MOZ-CBP <1
t(7;11) NUP98-HOXA9 <1
t(12;22) MN1-TEL <1
inv(3) RPN1-EVI1 <1
t(16;21) FUS-ERG <1
Table 3. Acute myeloid leukemia (AML)-associated Oncofusion proteins.
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